Intestinal burying of the jejunal-tube of a PEG-J levodopa-carbidopa release system for Parkinson's disease. Successful endoscopic management.

Óscar Moralejo LozanoAdrián Joaquín Barrajón MasaMichel Colmenares Bulgheroni

Published in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2021)

Levodopa-carbidopa intestinal gel (LCIG) continuous infusion into the jejunum through a percutaneous endoscopic gastrostomy with a jejunal extension (PEG-J) is an alternative therapy for Parkinson's disease (PD) patients, with a very poor control of their symptoms on regular oral medications (Hoehn-Yahr stage IV). Around 62.2 % of patients present procedure and device-related adverse effects (AE), with an 8.2 % rate of mayor complications.

Keyphrases

ultrasound guided
end stage renal disease
parkinson disease
drug delivery
ejection fraction
newly diagnosed
minimally invasive
deep brain stimulation
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
radiofrequency ablation
endoscopic submucosal dissection